Takeda Stock Rises After Positive Phase 3 Results for Narcolepsy Drug

Takeda stock rises after positive Phase 3 results for narcolepsy drug

Takeda's narcolepsy programme gets back on track

Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.

Takeda to seek approval of new kind of narcolepsy drug after study data

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that targets orexin proteins.

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass. -- Takeda ( TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to addres…

Targeted Narcolepsy Drug Shows Promising Results in Phase III

Takeda announced this week that its candidate small molecule oral drug, oveporexton, for treating type I narcolepsy achieved good results in two key Phase III trials, which the big pharma hopes will lead to regulatory approval. Type I narcolepsy is thought to affect around 126,000 people in the United States, but is likely underdiagnosed, so the actual number of people affected is probably higher. It is caused by a loss of neurons in the brain t…

Takeda Advances Orexin-Targeting Narcolepsy Drug Towards Approval

Takeda Pharmaceuticals is set to seek approval for its novel narcolepsy drug, oveporexton, following successful results from late-stage Phase 3 trials. This medication, previously known as TAK-861, targets orexin proteins and is the first of its kind to address narcolepsy Type 1—a condition characterized by excessive daytime sleepiness and muscle weakness. In the trials, oveporexton met all primary and secondary endpoints, showing significant im…